Immunotherapy ovarian cancer clinical trials
Witryna28 sie 2024 · Several studies have evaluated the efficacy of PD-1/PD-L1 inhibitors in ovarian cancer; however, the response rate varies. This study aims to explore the efficacy of anti-PD-1/PD-L1 therapy in ovarian cancer. A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the … Witryna12 kwi 2024 · Ovarian cancer (OC) is the fifth most common cause of cancer death. More than 40% are older than 70 years. The standard treatment is radical surgery …
Immunotherapy ovarian cancer clinical trials
Did you know?
Witryna27 sty 2015 · This is a multicenter, randomized, double-blind, placebo-controlled, Phase 2 study of maintenance Vigil Ovarian (gemogenovatucel-T) engineered autologous tumor cells (EATC) in women with Stage IIIb, IIIc or IV high-grade papillary serous/ clear cell / endometrioid ovarian, fallopian tube or primary peritoneal cancer. Witryna1 dzień temu · The first patient has been dosed in a phase 1/2 clinical study assessing the immunotherapy KVA12123 alone and with Keytruda (pembrolizumab) for the treatment of patients with advanced solid tumors. KVA12123 is a novel immunotherapy aimed at blocking VISTA, a protein highly expressed in renal cell carcinoma, …
Witryna202406106. A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian … Witryna13 kwi 2024 · The researchers investigated the immunological environment of different tumours and distinguished two different classes. In one class (consisting of melanoma, bladder cancer, and lung cancer), the immunogenic environment displayed typical signs of being supportive for immunotherapy, and accordingly, most of these patients …
WitrynaBreastCancerTrials.org Nationwide matching service for individuals diagnosed with or at risk for breast cancer, developed by UCSF. ClinicalTrials.gov Registry of all clinical trials — for cancer and other medical conditions — from the National Institutes of Health (NIH) 877-827-3222. WitrynaIn fact, all of the effective cancer treatments that are available today are based on the results of past clinical trials. To learn more about the ovarian cancer clinical trials being conducted by the cancer experts at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
Witryna1 dzień temu · During the past decade, findings from many clinical studies and analyses involving ICIs directed at PD-1/PD-L1 and CTLA-4 have led to the development of “a …
Witryna10 kwi 2024 · Newly diagnosed or recurrent gynecological cancer confirmed by histology. Age ≥ 20 years old. Expected to receive immunotherapy. Exclusion Criteria: … know when i don\u0027t wanna comeWitryna2 dni temu · Treatment with mirvetuximab soravtansine elicited improved responses when used for the treatment of patients with FRa-high platinum-resistant ovarian … know whats up lyricsWitryna11 maj 2024 · New York, May 11, 2024. The Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) announced today that the first patients … redbarn lamb lung training treats